142 lines
No EOL
28 KiB
XML
142 lines
No EOL
28 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548515" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548515/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Nelarabine - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Nelarabine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/05/01" /><meta name="citation_pmid" content="31643833" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548515/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Nelarabine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/05/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548515/" /><meta name="description" content="Nelarabine is a purine analogue and antineoplastic agent used in the therapy of T cell lymphoblastic leukemia or lymphoma. Nelarabine is associated with a low rate of transient serum enzyme elevations during therapy and has been linked to rare instances of clinically apparent acute liver injury with jaundice." /><meta name="og:title" content="Nelarabine" /><meta name="og:type" content="book" /><meta name="og:description" content="Nelarabine is a purine analogue and antineoplastic agent used in the therapy of T cell lymphoblastic leukemia or lymphoma. Nelarabine is associated with a low rate of transient serum enzyme elevations during therapy and has been linked to rare instances of clinically apparent acute liver injury with jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548515/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Nelarabine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548515/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C225C7D7E2EA100000000007F0068.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548515_"><span class="title" itemprop="name">Nelarabine</span></h1><p class="small">Last Update: <span itemprop="dateModified">May 1, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Nelarabine.OVERVIEW"><h2 id="_Nelarabine_OVERVIEW_">OVERVIEW</h2><div id="Nelarabine.Introduction"><h3>Introduction</h3><p>Nelarabine is a purine analogue and antineoplastic agent used in the therapy of T cell lymphoblastic leukemia or lymphoma. Nelarabine is associated with a low rate of transient serum enzyme elevations during therapy and has been linked to rare instances of clinically apparent acute liver injury with jaundice.</p></div><div id="Nelarabine.Background"><h3>Background</h3><p>Nelarabine (ne lar' a been) is a purine analogue that is used in the treatment of T cell leukemia or lymphoma. Nelarabine is arabinosyl derivative of deoxyguanosine (2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9-H-guanine) that, after removal of the methoxy group by adenosine deaminase in serum, is taken up and converted intracellularly to the active triphosphate, which is believed to compete with guanine triphosphate for use by DNA polymerase leading to inhibition of DNA synthesis. It has selective activity against T lymphocytes and was found to have activity against acute T cell malignancies. Nelarabine was approved for use as an antineoplastic agent in the United States in 2005. Current indications are therapy of acute T cell lymphoblastic leukemia and T cell lymphoblastic lymphoma after failure of prior therapies. Nelarabine is available as a solution for injection under the trade name Arranon. The typical adult dose is 1500 mg/m<sup>2</sup> intravenously on days 1, 3 and 5 of 21-day cycles. Common side effects include bone marrow suppression, nausea, vomiting, anorexia, diarrhea, headache, fatigue, mucositis and skin rash. The major dose limiting side effects of nelarabine are neurologic, including somnolence, headache, dizziness, ataxia, delirium, seizures, neuropathy and Guillain Barre syndrome. The neurologic toxicities can be severe and some are not reversible on stopping nelarabine as is stressed by the boxed warning in the product label.</p></div><div id="Nelarabine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In clinical trials, serum enzymes elevations occurred in a small proportion of patients treated with nelarabine when given as sole therapy for refractory or relapsed acute leukemia. These elevations are generally mild-to-moderate, transient and asymptomatic. Elevations of aminotransferase levels above 5 times the upper limit of normal are reported in 4% of patients with leukemia receiving nelarabine. The elevations rarely require dose adjustment or delay in therapy. Cases of clinically apparent liver injury due to nelarabine have been reported to occur, but few details are available. A single case report of clinically apparent liver injury attributed to nelarabine has been published with rapid onset of jaundice during a second course of nelarabine, a hepatocellular pattern of enzyme elevations, no immunoallergic or autoimmune features and a rapid improvement upon stopping.</p><p>Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury).</p></div><div id="Nelarabine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Hepatotoxicity from nelarabine is likely due to direct toxicity as is typical for other purine analogues.</p></div><div id="Nelarabine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of the liver injury linked to nelarabine therapy is generally self-limited and mild and resolves with stopping therapy. There is little evidence of cross sensitivity to liver injury among the various antineoplastic or antiviral purine analogues.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, Antimetabolites</p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/PurineAnalogues/">Purine Analogues</a>: <a href="/books/n/livertox/Azathioprine/">Azathioprine</a>, <a href="/books/n/livertox/Cladribine/">Cladribine</a>, <a href="/books/n/livertox/Clofarabine/">Clofarabine</a>, <a href="/books/n/livertox/Fludarabine/">Fludarabine</a>, <a href="/books/n/livertox/Mercaptopurine/">Mercaptopurine</a>, <a href="/books/n/livertox/Pentostatin/">Pentostatin</a>, <a href="/books/n/livertox/Thioguanine/">Thioguanine</a></p></div></div><div id="Nelarabine.PRODUCT_INFORMATION"><h2 id="_Nelarabine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
||
<b>REPRESENTATIVE TRADE NAMES</b>
|
||
</p><p>Nelarabine – Generic, Arranon®</p><p>
|
||
<b>DRUG CLASS</b>
|
||
</p><p>Antineoplastic Agents</p><p>
|
||
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fffa5d75-0dba-4ad7-a252-5f60fa28489a" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
||
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Nelarabine.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Nelarabine_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Nelarabine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548515/table/Nelarabine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nelarabine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Nelarabine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Nelarabine.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Nelarabine.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Nelarabine.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Nelarabine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nelarabine</td><td headers="hd_b_Nelarabine.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135108408" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">121032-29-9</a>
|
||
</td><td headers="hd_b_Nelarabine.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C11-H15-N5-O5</td><td headers="hd_b_Nelarabine.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135108408" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135108408" alt="image 135108408 in the ncbi pubchem database" /></a>
|
||
</td></tr></tbody></table></div></div></div><div id="Nelarabine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Nelarabine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 01 May 2020</p><p>Abbreviations: ALL, acute lymphocyte leukemia; HCT, hematopoietic cell transplantation.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Nelarabine.REF.zimmerman.1999">Zimmerman HJ. Oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 673-708.<div><i>(Expert review of hepatotoxicity of cancer chemotherapeutic agents published in 1999 discusses the purine analogues pentostatin, cladribine and fludarabine but not clofarabine or nelarabine).</i></div></div></li><li><div class="bk_ref" id="Nelarabine.REF.deleve.2013">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 541-68.<div><i>(Review of hepatotoxicity of hepatotoxicity of anticancer agents does not discuss nelarabine).</i></div></div></li><li><div class="bk_ref" id="Nelarabine.REF.chabner.2011">Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan DP. Purine analogs. Cytotoxic agents. Chemotherapy of neoplastic diseases. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1701-5.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Nelarabine.REF.kisor.2005.1056">Kisor DF. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. <span><span class="ref-journal">Ann Pharmacother. </span>2005;<span class="ref-vol">39</span>:1056–63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15870141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15870141</span></a>]<div>
|
||
<i>(Analysis of structure, mechanism of action, pharmacokinetics, efficacy and safety of nelarabine in T cell malignancies mentions that the dose limiting toxicity is neurological; no discussion of hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.gandhi.2006.584">Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. <span><span class="ref-journal">Curr Opin Oncol. </span>2006;<span class="ref-vol">18</span>:584–90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16988579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16988579</span></a>]<div>
|
||
<i>(Review of clofarabine and nelarabine, both of which had been recently approved for use in ALL and T cell leukemia or lymphoma, dose limiting toxicities being hepatic for clofarabine, neurologic for nelarabine).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.czuczman.2007.97">Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, et al. Cancer and Leukemia Group B. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. <span><span class="ref-journal">Leuk Lymphoma. </span>2007;<span class="ref-vol">48</span>:97–103.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17325852" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17325852</span></a>]<div>
|
||
<i>(Among 18 adults with T cell lymphomas treated with nelarabine, none had ALT or AST elevations during therapy, but neurologic toxicity was common [33%] and dose limiting).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.buie.2007.1887">Buie LW, Epstein SS, Lindley CM. Nelarabine: a novel purine antimetabolite antineoplastic agent. <span><span class="ref-journal">Clin Ther. </span>2007;<span class="ref-vol">29</span>:1887–99.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18035189" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18035189</span></a>]<div>
|
||
<i>(Review of the structure, mechanism of action, pharmacokinetics, clinical efficacy and safety of nelarabine encountered in preapproval trials; discusses the neurologic and hematologic, but not hepatic toxicities of nelarabine).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.cohen.2008.709">Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. <span><span class="ref-journal">Oncologist. </span>2008;<span class="ref-vol">13</span>:709–14.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18586926" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18586926</span></a>]<div>
|
||
<i>(Summary of the evidence for efficacy and safety of nelarabine in T cell leukemia and lymphoma which led to its approval in refractory or relapsed cases; the major dose limiting toxicity was neurologic, elevations of ALT levels above 5 times the ULN occurred in 4% of patients; no mention of clinically apparent liver injury).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.iino.2009.49">Iino M. <span><span class="ref-journal">Rinsho Ketsueki. </span>2009;<span class="ref-vol">50</span>:49–51.</span> [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma] Japanese. [<a href="https://pubmed.ncbi.nlm.nih.gov/19225230" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19225230</span></a>]<div>
|
||
<i>(41 year old man with T cell lymphoma after HCT developed liver test abnormalities at the end of a second course of nelarabine [peak bilirubin 17.7 mg/dL, ALT 2149 U/L, Alk P 704 U/L], resolving within 1 month of stopping with prednisolone and ursodiol treatment).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.commander.2010.345">Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">150</span>:345–51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20528871" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20528871</span></a>]<div>
|
||
<i>(Among 7 children with T cell leukemia treated with nelarabine in combination with etoposide and cyclophosphamide, 6 developed neurological toxicities, mostly pain, headache, somnolence, dizziness, neuropathy, tremor and ataxia; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.dunsmore.2012.2753">Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, Carroll WL, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>:2753–9.</span> [<a href="/pmc/articles/PMC3402886/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3402886</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22734022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22734022</span></a>]<div>
|
||
<i>(Among 92 children with T cell leukemia, 72 received nelarabine in addition of standard therapy; ALT and AST elevations occurred in 44% on nelarabine and in 56% who were not; neurologic side effects were more common with nelarabine, 11 developing neuropathy, 4 seizures and 1 a Guillain Barre-like syndrome).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.winter.2015.1176">Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2015;<span class="ref-vol">62</span>:1176–83.</span> [<a href="/pmc/articles/PMC4433576/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4433576</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25755211" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25755211</span></a>]<div>
|
||
<i>(Among 94 patients with acute T-cell leukemia or lymphoma treated with standard chemotherapy [usually methotrexate and pegaspargase] with or without nelarabine, rates of neuropathy were similar with or without nelarabine; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.zwaan.2017.284">Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. <span><span class="ref-journal">Br J Haematol. </span>2017;<span class="ref-vol">179</span>:284–93.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28771663" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28771663</span></a>]<div>
|
||
<i>(Among 28 children or young adults with acute T cell leukemia or lymphoma treated with 1-5 cycles of nelarabine, median survival was 6.5 months and adverse events were common, with 5 cases of neurologic adverse events but ALT elevations above 5 times the ULN in only one patient).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.kadia.2017.1">Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. <span><span class="ref-journal">Expert Rev Hematol. </span>2017;<span class="ref-vol">10</span>:1–8.</span> [<a href="/pmc/articles/PMC5578611/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5578611</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27869523" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27869523</span></a>]<div>
|
||
<i>(Review of the published literature on the efficacy and safety of nelarabine as therapy of acute T-cell leukemia and lymphoma, mentions the hematologic and neurologic toxicities which are frequent and are dose related; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Nelarabine.REF.abaza.2018.91">Abaza Y, M, Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <span><span class="ref-journal">Am J Hematol. </span>2018;<span class="ref-vol">93</span>:91–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29047158" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29047158</span></a>]<div>
|
||
<i>(Among 67 patients with acute T-cell leukemia or lymphoma treated with hyper-CVAD and nelarabine, the response rate was 96% and 3 year survival 66%, while adverse events occurred in all patients and were grade 3 or above in 91% with ALT elevations arising in 91% which were above 5 times ULN in 27%; no mention of clinically apparent hepatic adverse events).</i>
|
||
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548515</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643833" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643833</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Nefazodone/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Nelfinavir/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548515&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548515/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |